Home › Cancro ai polmoni › Massachusetts › Boston
Studi clinici su Cancro ai polmoni a Boston, MA
62 studi su Cancro ai polmoni cercano partecipanti presso sedi a Boston e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
In reclutamentoFase 3
- Boston Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
In reclutamento
- Dana-Farber Cancer Institute, Boston
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
In reclutamentoFase 3
- Tufts Medical Center, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
In reclutamentoFase 3
- Dana-Farber Cancer Institute, Boston
A Study of PHN-012 in Patients With Advanced Solid Tumors
In reclutamentoFase 1
- PHN-012-001 Site, Boston
A Registry for People With Lung Cancer
In reclutamentoStudio osservazionale
- Massachusetts General Hospital Cancer Center (Data Collection Only), Boston
- Brigham and Women's Hospital (Data Collection Only), Boston
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
In reclutamentoFase 2/3
- Dana-Farber Cancer Institute, Boston
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
In reclutamentoFase 2
- Research Site, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
In reclutamentoFase 2/3
- Dana-Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
In reclutamentoFase 1/2
- Massachusetts General Hospital - Main Campus, Boston
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
In reclutamentoFase 1
- Dana-Farber Cancer Institute, Boston
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
In reclutamentoFase 1
- Dana Farber Cancer Institute, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
In reclutamentoFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
In reclutamentoFase 3
- Massachusetts General Hospital, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
In reclutamentoFase 3
- Boston Medical Center, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
In reclutamentoFase 1/2
- Avenzo Therapeutics Recruiting Site, Boston
Investigating Hereditary Risk In Thoracic Cancers (INHERIT)
In reclutamentoStudio osservazionale
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
LEGACY: Lung Cancer Screening in Individuals With a Lung Cancer Family History-Protocol B
In reclutamentoStudio osservazionale
- Massachusetts General Hospital, Boston
Practical Geriatric Assessment in Older Adults With Non-Small Cell Lung Cancer Undergoing Stereotactic Body Radiation Therapy
In reclutamento
- Brigham and Women's Hospital, Boston
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Dana Farber Cancer Institute, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
In reclutamentoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
Preliminary Efficacy of Different Exercise Training During Immunotherapy in Patients With Lung Cancer: The ENHANCE Trial
In reclutamento
- Dana-Farber Cancer Institute, Boston
Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study
In reclutamento
- Dana-Farber Cancer Institute, Boston
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
In reclutamentoVolontari sani benvenuti
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC
In reclutamentoFase 2
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer
In reclutamento
- Massachusetts General Hospital, Boston
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Clonal Hematopoiesis Chemotherapy and Radiation Effects Study
In reclutamentoStudio osservazionale
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
In reclutamentoFase 1
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
Prediction Augmented Screening Initiative
In reclutamento
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
In reclutamentoFase 1
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
In reclutamentoFase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
In reclutamentoFase 1/2
- Massachusetts General Hospital,, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Deep Learning Using Chest X-Rays to Identify High Risk Patients for Lung Cancer Screening CT
In reclutamento
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
In reclutamentoFase 1/2
- Massachusetts General Hospital, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Avecure Flexible Microwave Ablation Probe For Lung Nodules
In reclutamento
- Beth Israel Deaconess Medical Center, Boston
A Digital Health Intervention to Improve Physical Function and Wellness of Lung Cancer Survivors
In reclutamento
- Massachusetts General Hospital, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
In reclutamentoFase 1/2
- Dana-Farber Cancer Institute, Boston
Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers
In reclutamentoVolontari sani benvenuti
- Massachusetts General Hospital (MGH) / Harvard, Boston
Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection Specimens
In reclutamentoVolontari sani benvenuti
- Brigham and Womens Hospital, Boston
Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
In reclutamentoFase 2
- Massachusetts General Hospital, Boston
Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients
In reclutamentoFase 1Volontari sani benvenuti
- Massachusetts General Hospital, Boston
Lung Cancer Screening in High-risk Black Individuals
In reclutamentoVolontari sani benvenuti
- Massachusetts General Hospital Cancer Center, Boston
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
In reclutamento
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
Stereotactic Magnetic Resonance Guided Radiation Therapy
In reclutamento
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Image Guided VATS vs. VATS Resection
In reclutamento
- Brigham and Women's Hospital, Boston
Health Opportunities and Promoters of Equitable Screening for Lung Cancer
In reclutamentoStudio osservazionale
- Massachusetts General Hospital, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
In reclutamentoFase 1/2
- Dana Farber Cancer Institute, Boston
Comprehensive Outcomes for After Cancer Health
In reclutamentoVolontari sani benvenuti
- Dana Farber Cancer Institute, Boston
DNA Analysis of Blood and Tissue from Patients with Lung Cancer
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Massachusetts General Hospital, Boston
- Harvard School of Public Health, Boston
Molecular and Genetic Analysis of Lung Cancer
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Massachusetts General Hospital, Boston
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier
In reclutamentoStudio osservazionale
- Boston University Medical Center, Boston
Studi su Cancro ai polmoni in altre città
- Houston, TX78 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Washington, DC41 studi
- Arlington, VA41 studi
- Chicago, IL41 studi
- Nashville, TN40 studi
- Baltimore, MD40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
- Seattle, WA33 studi
Altri studi a Boston
- Cancro al seno111 studi
- Cancro del polmone non a piccole cellule90 studi
- Cancro (tutti i tipi)86 studi
- Cancro colorettale63 studi
- Cancro metastatico63 studi
- Cancro ovarico61 studi
- Cancro alla prostata59 studi
- Depressione52 studi
- Cancro dell'endometrio50 studi
- Insufficienza cardiaca44 studi
- Leucemia mieloide acuta44 studi
- Cancro pancreatico43 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.